Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...

BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based ...

One study suggests these drugs could increase depression risk in heart attack survivors who retained normal heart pumping ...

Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, is the leading cause of acquired heart disease in developed countries, with the potential of ...

In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...